1. Home
  2. LAW vs ADCT Comparison

LAW vs ADCT Comparison

Compare LAW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$3.42

Market Cap

466.2M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.18

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
ADCT
Founded
2013
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.2M
484.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
LAW
ADCT
Price
$3.42
$4.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$8.00
$7.50
AVG Volume (30 Days)
608.6K
717.8K
Earning Date
05-25-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
44.90
EPS
N/A
N/A
Revenue
$156,849,000.00
$70,837,000.00
Revenue This Year
$9.74
$13.66
Revenue Next Year
$9.78
$2.15
P/E Ratio
N/A
N/A
Revenue Growth
8.29
1.84
52 Week Low
$2.45
$1.05
52 Week High
$9.11
$4.80

Technical Indicators

Market Signals
Indicator
LAW
ADCT
Relative Strength Index (RSI) 38.28 54.89
Support Level N/A $3.25
Resistance Level $4.48 $4.32
Average True Range (ATR) 0.41 0.25
MACD 0.09 -0.00
Stochastic Oscillator 65.64 48.29

Price Performance

Historical Comparison
LAW
ADCT

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: